Proceedings of the International scientific and practical conference ―New York Global Science Conference 2026‖ (May 18-20, 2026) / Publisher website: www.naukainfo.com. – New York, USA, 2026. - 322 p.

248 (n=30). Heart rate (HR), systolic (SBP) and diastolic blood pressure (DBP), total cholesterol (TC), low-density lipoproteins (LDL), high-density lipoproteins (HDL), uric acid (UA), and left ventricular ejection fraction (LVEF) were assessed. Statistical analysis was performed using parametric and non-parametric tests; differences were considered significant at p<0.05. Comprehensive therapy combined with β-AB or CCB contributed to a significant improvement in haemodynamic and metabolic parameters. Both groups showed a reduction in HR, SBP, DBP, TC, and LDL levels, and an increase in HDL (p<0.001). β-AB therapy produced a more pronounced decrease in HR (−13.2%, p<0.005) and improvement in the lipid profile (TC −24.8%, LDL −28.6%, HDL +66.9%, p<0.001). CCBs provided a greater reduction in blood pressure (SBP −14.3%, DBP −6.3%, p<0.001 and p<0.005, respectively) with a similar effect on lipid metabolism. Both groups showed a tendency toward a decrease in UA levels (β-AB −6.5%, CCB −4.1%, p>0.1) and LVEF remained stable within normal limits. Comprehensive therapy with β-AB or CCB in patients with CHD and AH improves haemodynamic and lipid metabolism parameters. β-AB primarily reduces heart rate and sympathetic activity, while CCBs have a more pronounced antihypertensive effect. The results highlight the need for an individualised approach to the selection of antianginal therapy based on the patient's clinical profile. Keywords: coronary heart disease, arterial hypertension, β-adrenoblockers, calcium channel blockers, lipid metabolism, haemodynamics. Introduction Cardiovascular diseases (CVDs) remain the leading cause of morbidity, disability, and mortality worldwide, accounting for more than one-third of all deaths among the adult population. Coronary heart disease (CHD) and arterial hypertension (AH) represent the most common combination of pathologies in the clinical practice of internal medicine. Their coexistence leads to a more severe clinical course, increases the risk of heart failure, rhythm disturbances, and sudden cardiac death. Effective management of such patients requires a comprehensive pharmacological approach that not only corrects blood pressure and symptoms of